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Endometriosis is a common gynecological disease affecting women in their best reproductive years. 
It is divided into three forms depending on the location and depth of the disease; superficial 
peritoneal endometriosis, ovarian endometriosis and deep infiltrating endometriosis (DIE). DIE 
located in the rectovaginal septum is referred to as rectovaginal endometriosis (RVE). It causes 
severe pain via mechanisms that are partly unknown. Inflammation and increased innervation in 
endometriotic tissue appear to have a central role in the generation of these symptoms. 
The first-line treatment of endometriosis, RVE included, is hormone therapy using combined oral 
contraceptives (COCs) or progestins. In cases of RVE, however, this is not always sufficient. In 
symptomatic patients not responding to hormonal therapies (HTs), radical surgery is needed – 
meaning excising all the visible endometriotic tissue from the pelvic and abdominal areas. Surgical 
treatment of RVE extending into colorectum may require bowel resection. The long-term effects of 
surgery for RVE have not been well studied. The ultimate aim of this study was to acquire 
information on the long-term outcome of RVE surgery. 
Patient charts concerning RVE surgery (153 cases) between 2000–2004 were studied to investigate 
the outcome (Study I). In addition, we aimed to identify factors associated with bowel surgery; for 
adequate patient counseling and operative planning, patients who need colorectal surgery should be 
identified early on. 
To study the long-term effects of surgery, patients operated upon in 2002–2004 were offered a 
follow-up visit to our clinic on average four years after the original operation. Altogether, 60 patients 
agreed to take part in this study (Study II). Symptom recurrence was evaluated by using symptom 
diaries. 
We also studied charts on 164 patients who had undergone bowel resection in 2004–2012. The 
laparoscopic approach to bowel resection was of special interest (Study III), with emphasis on 
collecting information on complications. 
Since increased densities of nerve fibers in endometriotic tissue may contribute to pain generation, 
we used immunohistochemistry to study their types and presence in samples obtained during 
surgery in 2000–2004. Altogether, 45 samples were eligible for this study (Study IV). We also studied 
the effects of HT on the density of nerve fibers. 
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Our results showed that even though clinical recurrence developed in 35% of cases, symptom 
recurrence was rare. Bowel resection was protective as regards recurrence, as were all the forms of 
hormone and surgical therapy that resulted in amenorrhea. 
Laparoscopy offers a safe route for performing RVE surgery, and should be the primary approach 
even as regards colorectal resection in cases of RVE. We found that the rate of complications did not 
depend on the type of surgery (laparoscopy vs. laparotomy) but was more related to the experience 
of the surgeon. 
Excessive innervation by sympathetic, parasympathetic and sensory nerve fibers was identified in the 
surgical RVE specimens. This innervation may be one of the explanations for the severe pain that 
these patients experience. The density of nerve fibers was reduced among those patients who were 
using either COCs or progestins.  
In conclusion, in experienced hands, surgery for RVE results in long-term symptom relief. In order to 
avoid symptom recurrence, HTs with the aim of amenorrhea should be administered following 
surgical treatment. Reducing the densities of nerve fibers in endometriotic tissue may be a novel 
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Endometriosis is a benign estrogen-dependent disease occurring in 6-10% of women of reproductive 
age (Lebovic et al., 2001, Giudice, 2010). It is frequently associated with severe pain symptoms such as 
dysmenorrhea, dyspareunia (pain during intercourse) or chronic pelvic pain. Endometriosis is also a 
common cause of infertility.  
Three different forms of endometriosis have been recognized, depending primarily on the location of 
the disease – ovarian endometriosis, superficial peritoneal endometriosis and deep infiltrating 
endometriosis (DIE). DIE is commonly located in the utero-sacral ligaments, the cul-de-sac, or the 
upper posterior vaginal wall behind the cervix – in the last case, endometriosis is referred to as 
rectovaginal endometriosis (RVE). In 4–12% of RVE cases, DIE extends into the bowel wall (Wills et 
al., 2008).  
Pain is the leading symptom in endometriosis. However, the origin of this pain remains enigmatic. 
Inflammation is considered the main factor in generating endometriosis-associated pain (Bergqvist 
et al., 2001, Sikora et al., 2012, Ahn et al., 2015). Estrogen is involved in promoting inflammation 
(Bulun 2009). In addition, endometriotic lesions – and RVE in particular – show a dense innervation 
by small unmyelinated nerve fibers (Tokushige et al., 2007). Hyperinnervation and inflammation 
seem to be closely connected as inflammation induces the release of several neurotrophic factors, 
which subsequently lead to nerve sprouting and pain (Maharajaa et al., 2014, McKinnon et al., 2015).  
Various forms of hormone therapy (HT), in particular COCs and progestogens, are used as the first-
line treatment for pain in RVE (Vercellini et al., 2009), since HT suppresses ovarian estrogen 
secretion, and reduces inflammation. However, other mechanisms of action may be involved as well; 
the decrease in retrograde menstruation, and the subsequent reduction of inflammatory agents of 
endometrial origin may also contribute to achieving pain relief. Interestingly, HT has also been 
shown to reduce the density of nerve fibers in lesions, adding possibly a completely novel 
explanation for its mechanism of action (Tokushige et al., 2009). 
In RVE patients not responding to hormone therapy, the gold standard for treatment is surgery 
(Chapron et al., 2004). The surgical treatment of RVE is challenging, and preservation of fertility is 
demanded in most operations. A multidisciplinary approach is often needed, as in 35% of cases 
surgery involves bowel resection (Meuleman et al.,2011). During the past ten years, the route in 
performing bowel resection has changed from laparotomy to a laparoscopic approach (Ruffo et al., 
2012). In large specialized centers, major complications occur in 9% of laparoscopic bowel resections 
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(Ruffo et al., 2012). It would be extremely important to identify patients requiring colorectal surgery 
in advance for adequate patient information and optimal planning of surgery.  
Recurrences – return of lesions or pain – following endometriosis surgery present a major challenge. 
They occur in 25-30% of all endometriosis operations (Vercellini et al., 2009). Recurrence rates 
following RVE surgery vary between 3–35% (Fedele et al., 2004). Performing bowel resection may be 
protective against recurrence (Fedele et al. 2004). However, more studies are needed to identify 
factors associated with recurrence. 
The aim of the present work was to study the long-term effects of surgery in the treatment of RVE, 
and in particular, to identify factors connected with recurrence. Also, an important aim was to 
identify patients requiring colorectal surgery, and to recognize factors associated with performing 
bowel resection. The feasibility of a laparoscopic approach to bowel resection among RVE patients 
needed evaluation as well, since the majority of these operations in Helsinki University Central 
Hospital are currently performed via laparoscopy. As nerve fibers may have a central role in 
generating pain, the densities of nerve fibers in endometriotic tissue removed during surgery were 





















Endometriosis is a chronic, benign, estrogen-dependent inflammatory disease defined as the 
presence of endometrial glands and stroma outside the uterus (Giudice & Kao, 2004). The most 
typical locations of endometriotic lesions are illustrated in Figure 1. Depending on the location, 
endometriosis is divided into superficial peritoneal endometriosis, ovarian endometriosis, or deep 
infiltrating endometriosis (DIE). Endometriotic implants penetrating the peritoneum deeper than 5 
mm are defined as cases of DIE (Koninckx, 1991). In the literature, DIE is also referred to as 
adenomyosis externa because of the histological resemblance of these noduli (nodular aggregates of 
smooth muscle cells) to adenomyomas (Koninckx et al., 2012). The adenomyotic nodules typically 
involve the pouch of Douglas, the vesicouterine fold, the uterosacral ligaments, the upper vaginal 
wall behind the cervix, and/or the rectosigmoid colon.  
Rectovaginal endometriosis (RVE) refers to DIE that extends from the posterior upper vaginal wall to 
the anterior rectal wall, and laterally to the uterosacral ligaments (Wolthuis et al., 2014). Recently, a 
precise definition of RVE has been suggested to be endometriosis of the retrocervical septum (Batt et 













Figure 1. Typical locations of ectopic endometriotic lesions.  
1. ovaries 
2. bowel wall 
3. sacrouterine ligaments 









2. Prevalence and significance of endometriosis 
 
Endometriosis affects up to 6–10% of women of reproductive age (Giudice and Kao 2004, Gylfason et 
al., 2010). It is much more common among patients suffering from chronic pelvic pain and/or 
infertility, when its frequency can reach up to 35–50% (Giudice and Kao 2004). RVE is less common 
than ovarian or peritoneal endometriosis, affecting only 1% of women of fertile age (Slack et al., 2007, 
Koninckx et al., 2012). However, the presence of DIE is often underestimated; in a recent study 
among endometriosis patients undergoing surgery, the prevalence of DIE was 22%, and in 65% of 
DIE cases patients presented with a rectovaginal nodule (Knabben et al., 2015). 
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A prospective, multicenter study conducted in 10 European countries demonstrated that the average 
annual cost per patient with endometriosis was approximately 10 000 euros in 2008, including both 
health care and loss of productivity costs (Simoens et al., 2012). In a recent Danish study, 
endometriosis associated with impaired working ability (Hansen et al., 2013). Other inflammatory 
diseases (such as painful bladder syndrome, migraine or irritable bowel syndrome) as well as 
autoimmune diseases and asthma frequently coincide with the condition, adding to the economic 





Patients with endometriosis suffer from a variety of pain symptoms depending on the location of the 
disease (Table 1). Subfertility can be the first sign of endometriosis. The two most common 
symptoms in endometriosis are dysmenorrhea and abdominopelvic pain; approximately 70% of 
patients with endometriosis report either of these symptoms (Vercellini et al., 2007, Ballard et al., 
2008). Curiously, no clear correlation exists between the extent of pelvic endometriosis in surgery, 
and the intensity of pain symptoms (Fauconnier and Chapron 2005). Severe preoperative symptoms, 
however, seem to be connected to the existence of deep lesions (Chapron et al., 2012). It has been 
estimated that over 95% of patients with DIE are symptomatic, and their quality of life can be 
compromised to a great extent due to these pain symptoms (for review see Koninckx et al., 2012).  
In RVE, due to the anatomic location, the main complaints are dysmenorrhea, dyspareunia, pelvic 
pain and pain during defecation (Chapron et al., 2012). If endometriotic lesions infiltrate into the 
bowel wall, patients may present with bowel symptoms such as rectal bleeding, bloating, diarrhea, or 
constipation. DIE located in the urinary tract may be associated with dysuria or hematuria. Ureteral 
stenosis by ectopic endometriotic tissue may lead to impaired kidney function, usually unilaterally 








Table 1. Typical symptoms in endometriosis. 
 
 
Symptoms   
Dysmenorrhea  
Non-cyclical pelvic pain  








4. Pathophysiology of endometriosis and pain 
 
No consensus exists concerning the mechanisms underlying the generation of endometriotic 
implants. The most accepted theory is that of Sampson, published as early as in 1927. According to 
this theory, endometriosis results from backward (retrograde) menstrual flow from the uterine cavity 
through the fallopian tubes to the peritoneal surfaces (Sampson, 1927). Thereafter, menstrual 
fragments implant and persist through a variety of inflammatory and angiogenic processes (for 
review see Bulun 2009) (Figure 2).  
Altered immunology – involving dysfunctional macrophages and other immune cells – seems to have 
a central role in the development of endometriosis (Lebovic et al., 2001, Vercellini et al.,2014). 
Macrophages synthesize and secrete prostaglandins, cytokines, growth factors and angiogenic 
factors into the peritoneal fluid, these including interleukins, TNF- , TGF- , VEGF, COX-2, and the 
neurotrophin NGF (Giudice and Kao 2004, Sikora et al., 2012, Ahn et al., 2015) (Figure 2.). Cytokines 
together with metalloproteinases act in the process of adhesion and implantation of endometrial 
fragments into the peritoneal surfaces (Sikora et al., 2012, Burney and Giudice 2012). RANTES 
(regulated on activation, normal T cell expressed and secreted) is a potent chemokine that attracts 
granulocytes and natural killer cells, and high concentrations of RANTES have been measured in the 
peritoneal fluid of endometriosis patients (Hornung et al., 1997). Inflammatory neurotrophins such 
as NGF seem to contribute to the increased nerve sprouting present in endometriosis. (Anaf et al., 
2002, McKinnon et al., 2015). 
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Sampson’s hypothesis of retrograde menstruation is supported by the observation that 
endometriosis is more common among patients who have vaginal obstruction of outflow (Olive and 
Henderson 1987). The more bleeding there is, the higher the risk of endometriosis; early menarche, 
and abundant, frequent menstruation seem to be risk factors for the development of the condition 
(Darrow et al., 1993).  
Of the alternative pathogenetic theories, the coelomic-metaplasia theory proposes that 
endometriosis results from the differentiation of mesothelial cells into endometrium-like tissue 
(Vinatier et al., 2001). A third theory proposes that endometrial-like tissue fragments may migrate 
into the peritoneal cavity through lymphatic vessels and veins (Sampson 1927). This lymphatic 
spread could explain the occurrence of distant endometriotic foci that have been observed in the 
pericardium, pleura, and even in the brain (Noel et al., 2008). Interestingly, in a study by Noel et al. 
(2008), lymph node involvement was observed in 42% of patients with rectosigmoid endometriosis.  
RVE has been suggested to have a pathophysiological origin that is different from other forms of 
endometriosis (Donnez et al., 1995). According to this theory, RVE originates from the Mullerian 















Figure 2. Mechanisms involved in the pathogenesis of endometriosis. EBAF=endometrial bleeding-
associated factor; HGF=hepatocyte growth factor; VEGF= vascular endothelial growth factor; MMP=matrix 




















4.1.  Central role of the endometrium  
 
Almost every fertile-aged woman has some degree of retrograde menstruation, while only 6–10% of 
them develop endometriosis. Thus, it is intriguing to think that the explanation might be in the 
endometrium. Interestingly, the endometrium of a woman with endometriosis actually is abnormal 
in several ways. It shows numerous molecular and enzymatic alterations that finally result in 
increased synthesis of cytokines, prostaglandins, metalloproteinases and estrogen (for reviews see 
Giudice and Kao, 2004, Bulun, 2009) (Figure 2.) These alterations may take place even in normal 
endometrium as a result of oxidative stress in the pelvic cavity, and this may be one of the 
explanations why some women develop endometriosis while others do not (Yun et al., 2016). The 
changes in the endometrium are not only vital for implant survival, but they also help to create an 
inflammatory environment optimal for nerve sprouting (Stratton and Berkley 2011).   
One of the fundamental features in endometriosis is the capacity of eutopic and ectopic 
endometrium to synthesize estrogen autonomously (Noble et al., 1997, Zeitoun et al., 1998). 
Aromatase is the enzyme that catalyzes conversion of androstenedione and testosterone, derived 
from ovarian and adrenal sources, to estrone, which in turn is converted to estradiol by 17 -
hydroxysteroid dehydrogenase 1. (Figure 3). This estrogen synthesis is increased in endometriosis 
patients while inactivation of estradiol to estrone by 17 -hydroxysteroid dehydrogenase 2 is impaired 
(Huhtinen et al., 2012). 
The overexpression of COX-2 (cyclooxygenase-2) in eutopic and ectopic endometrium results in 
increased prostaglandin E2 (PGE2) production, as COX-2 catalyzes the formation of PGE2 from its 
precursor (arachidonic acid). This cascade is further stimulated by high concentrations of estradiol 
(Noble et al. 1997) (Figure 3). PGE2 is involved in pain generation, causing uterine cramps and 
dysmenorrhea (Tsai et al., 2001, Sun et al., 2003).  
A reduction of progesterone action in the endometrium, ‘progesterone resistance’ of women with 
endometriosis (Osteen et al., 2005) may also play a role in escalating estrogen actions. The effects of 
progesterone – such as downregulating estrogen receptors – are mediated through binding to 
progesterone receptor B; progesterone receptor A represses the function of receptor B. In 
endometriotic implants progesterone receptor B is lacking and only the inhibitory receptor A is 





Figure 3.   
Relationship between estrogen synthesis and inflammation (modified from Bulun, 2005, in 
Pharmacological Reviews). 
A = androstenedione 
AA = arachidonic acid 
E1 = estrone 
E2 = estradiol 
CHOL = cholesterol 







4.2.  Nerve fibers in endometriosis 
 
During the past few years, new evidence has emerged on innervation of endometriotic implants. 
Direct innervation of endometriotic implants by sensory and sympathetic nerve fibers was first 
identified in a rat model (Berkley et al., 2004) and later in lesions from women with endometriosis 
(Berkeley et al., 2005). In 2006, small unmyelinated nerve fibers were recognized in the endometria 
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of women suffering from endometriosis (Tokushige et al., 2006). These nerve fibers were lacking in 
the endometria of healthy controls. This finding of increased innervation was later also recognized in 
peritoneal lesions (Tokushige 2006). Furthermore, these nerve fibers were more frequently seen near 
the endometriotic glands and blood vessels than elsewhere in the stroma. By using 
immunohistochemical staining with specific markers (Table 2), it was demonstrated that these nerve 
fibers were a mixture of myelinated A , unmyelinated sensory C, cholinergic and adrenergic nerve 
fibers (Tokushige 2006). Recently, a predominance of sensory fibers (proinflammatory fibers) has 
been identified (Arnold et al. 2012).  
Anaf et al. (2000) were the first to describe the presence of nerve fibers in women with rectovaginal 
endometriotic nodules. Women with more severe preoperative pain symptoms demonstrated a 
significantly higher density of nerve fibers within the endometriotic nodules. Thereafter, an 
increased density of nerve fibers in DIE lesions compared with peritoneal lesions was documented by 
Wang et al (2009). In particular, nerve fiber density was high in rectal lesions. Similar results of more 
nerve fibers in DIE compared with other sites were further confirmed by McKinnon et al (2012). 
 
Table 2. 








4.3.  Nerve fibers and pain – is there a connection? 
 
The clinical relevance of finding nerve fibers in endometriotic lesions is still somewhat controversial. 
According to the results of a study by Maharajaa et al. (2014), a statistically significant positive 
correlation exists between nerve fiber density and perimenstrual pain scores.  
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In a pilot study by Meschner et al. (2009), patients with peritoneal endometriosis with more severe 
pain symptoms (visual analogue scale [VAS] score 3) appeared to have more endometriosis-
associated nerve fibers in the peritoneum compared with patients with milder symptoms. This 
indicates that the excess of nerve fibers in endometriosis might be connected to clinical pain 
symptoms. Interestingly, in RVE nodules, there is a particularly rich innervation (Wang et al., 2009), 
and these women represent a group of patients with most distracting pain symptoms (Fauconnier 
and Chapron 2005). However, RVE often develops in anatomical sites that are richly innervated to 
begin with, such as the bowel wall or uterosacral ligaments. Therefore, hyperinnervation may only 
reflect a typical feature of these anatomical sites, and may not be connected to pain symptoms at all. 
McKinnon et al. (2012) have reported that the abundance of nerve fibers is associated with pain only 
in peritoneal endometriosis, and not in RVE.  
Recent studies unanimously show that inflammation associated with endometriosis induces the 
release of neurotrophic factors (such as NGF), which then lead to the generation of nerve fibers, and 




4.4.  The origin of nerves – association between nerve and vascular  growth 
 
It is well accepted that angiogenesis, the development of new blood vessels  from existing blood 
vessels, has an important role in the establishment and growth of endometriotic lesions (May and 
Becker 2008). VEGF and other angiogenic factors have been measured in high concentrations in 
peritoneal fluid from women with endometriosis (McLaren et al., 1996).  
The growth patterns of both blood vessels and nerve fibers are very similar processes, which share 
common pathways (Carmeliet and Tessier-Lavigne 2005). VEGF and NGF are key mediators of both 
angiogenesis and neurogenesis (Becker et al., 2011). In addition, when new endometriotic lesions 
develop vasculature, the vessels bring along sensory and adrenergic nerve supplies. 
Interestingly, different pathophysiological processes in endometriosis – neurogenesis, angiogenesis, 







5. Peripheral and central pain mechanisms in endometriosis 
 
The local effects of ectopic endometriotic tissue such as cyclical bleeding or compression of nerves 
may contribute to pain generation in endometriosis (Anaf et al., 2000, Fauconnier and Chapron 
2005). However, in recent years, the focus in endometriosis-associated pain research has moved from 
lesions towards understanding mechanisms involved in pain perception. The role of the CNS in this 
process is essential (Stratton and Berkley 2011). Transmission of pain stimuli to the CNS is illustrated 
in Figure 4. 
The release of pro-inflammatory factors from endometriotic tissue and immune cells into peritoneal 
fluid activates the nociceptors in sensory C-nerve fibers (Stratton and Berkley 2011). During 
inflammation, sensory C-fibers may simultaneously convey information to the CNS (afferent 
function) and at the same time release inflammatory peptides into the local environment. 
Sometimes these sensory C-fibers may start discharging inflammatory agents through an efferent 
function without any noxious stimuli (Zhang et al., 2008). This peripheral sensitization is the main 
mechanism in the development of neuropathic pain present in endometriosis. Central sensitization 
occurs through neural mechanisms identical to those underlying memory, in which case central pain 
perception becomes autonomous of any peripheral input (Stratton and Berkley 2011, Morotti et al., 
2014). Central sensitization may also explain why therapies targeted at the periphery, such as 
repeated surgery, may not relieve pain.  Similarly, the return of pain after surgery is sometimes seen 
without evidence of new lesions (Abbott et al., 2003) hence reflecting the neuropathic nature of pain. 
Interestingly, estrogen may somehow modulate pain perception in the periphery and the CNS, and 
its effects appear to be both pro-nociceptive and anti-nociceptive (Craft 2007). 
Pain is a stressful experience, and the hypothalamic–pituitary–adrenal (HPA) axis is also activated 
during pain. Stressful factors such as chronic pain result in increased secretion of CRH and 
vasopressin from the hypothalamus, which in turn stimulate pituitary ACTH secretion. This cascade 
leads to the release of glucocorticoids from the adrenals. Glucocorticoids have anti-inflammatory 
effects mediated mainly by suppression of cytokine activity (Joels et al., 2007). 
Monoaminergic neurons in the brain stem usually inhibit nociceptive transmission. However, with 
HPA activation, an increase in glucocorticoid secretion induces monoamine depletion (for review see 






Figure 4. Nociception and pain transmission. 
 
 
6. Non-hormonal medical treatment of pain  
 
6.1 Anti-inflammatory analgesics 
 
As the major symptom in endometriosis is pain, and the major pathophysiologic mechanism 
underlying this condition is inflammation, it is not surprising that nonsteroidal anti-inflammatory 
drugs (NSAIDs) have been widely used for pain alleviation in endometriosis. The mechanism of 
action of NSAIDs involves inhibition of the enzymes COX-1 and COX-2, hence reducing the 
production of prostaglandins. However, to date, little evidence exists on the effects of NSAIDs on 
endometriotic pain (Allen et al., 2009). No studies have been conducted on the use of NSAIDs in 
RVE. Some serious side effects have been connected to NSAID use, including peptic ulcers, acute 




7. Hormonal treatment of pain  
 
7.1 Use of GnRH analogues 
 
The rationale of using GnRH analogues is based on the suppression of ovarian estrogen production 
through downregulation of GnRH receptors at pituitary level, thereby lowering gonadotropin 
secretion. As a result, profound hypoestrogenism with amenorrhea is achieved. Even though GnRH 
analogues appear effective in achieving pain relief, their efficacy is limited to the period of 
medication use, which usually is six months (Brown and Farquhar 2014). Moreover, side effects due 
to hypoestrogenism such as hot flushes, urogenital atrophy, loss of libido, deterioration of the lipid 
profile, and bone mass decrease occur commonly in connection with GnRH analogues (Prentice 
2000). “Add-back therapy” with hormone replacement treatment may resolve these side effects and 
enable the use of GnRH analogues for longer periods of time. As GnRH analogues are also costly, 




7.2 Progestogens – why do they work? 
 
The Practise Committee of the American Society for Reproductive Medicine (2008) has stated that 
“endometriosis should be viewed as a chronic disease that requires a life-long management plan with 
the goal of maximizing the use of medical treatment and avoiding repeated surgical procedures”. 
Progestogens and COCs offer a good option for use on a long-term basis because of their good safety 
profile and low cost (Dunselman et al., 2014). 
Progestogens have been used in the symptomatic treatment of endometriosis for decades. They can 
be used either alone or combined with estrogens, as in COCs. The most common side effects 
reported in connection with progestogens are weight-gain and menstrual irregularities.  
Several interesting mechanisms of action have been recognized in connection with progestogens. 
They inhibit ovulation and thus suppress estrogen secretion from the ovaries in a dose-dependent 
manner. As endometriosis is estrogen-dependent, this mechanism offers a biological basis for their 
use. Progestogens also cause decidualization of the endometrium (Jones et al., 2000), and, therefore, 
antagonize estrogen actions. Subsequently, atrophy is achieved both in the eutopic endometrium 
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and in the ectopic implants. As endometriosis is thought to evolve as a consequence of retrograde 
menstruation and implantation of the regurgitated endometrium into the peritoneal surfaces 
(Sampson 1927), this mechanism of action may be fundamentally important in controlling the 
activity of disease and pain symptoms. Also, progestogens have anti-angiogenic (Blei et al. 1993) and 
anti-inflammatory properties (Zhao et al., 2002). The anti-inflammatory effect is most likely achieved 
by suppressing ovarian estrogen secretion, hence reducing estrogen-induced prostaglandin 
production (Bulun 2009).   
The effect of COCs on regulation of apoptosis in the endometrium has been studied by Meresman et 
al., (2002). Eutopic endometrial cells from patients with endometriosis show an increased survival 
capacity as a result of high expression of the proto-oncogene Bcl-2 (B cell lymphoma/ leukemia-
2),which blocks apoptosis (Meresman et al., 2002). The protein Bax antagonizes this effect, and the 
ratio of Bcl-2 to Bax is important in determining susceptibility to cell death (Chao and Korsmeyer 
1998). Administration of COCs appears to increase expression of the Bax gene, and consequently, 
apoptosis (Meresman et al., 2002). 
Endometriotic lesions – and RVE in particular - are richly innervated by small nerve fibers 
(Tokushige et al., 2006, Wang et al., 2009). The use of progestogens and COCs reduces the density of 
these nerve fibers (Tokushige 2008, 2009), which may result from progestogen-mediated reduction 
of NGF expression (Mita et al., 2014). Therefore, this new mechanism of action may add to the 
favorable effects of progestogens, and together with their anti-inflammatory, anti-angiogenic and 
immunomodulatory properties, constitute the basis for the efficacy of progestogens and COCs in 
endometriosis. 
 
7.3 Studies on progestogens and COCs in RVE 
 
Even though progestogens and COCs are widely used for the medical treatment of endometriosis, 
studies on their use in cases of RVE are few (Table 3).  
An intrauterine device that releases levonorgestrel at 20 μg/day over a 5-year period (the LNG-IUS) 
has a profound effect on the endometrium, rendering it atrophic and inactive (Nilsson et al., 1986). 
The endometrial decidualization has been described as being similar to that occurring during the 
first trimester of pregnancy (Chritchley et al., 1998). Therefore, a major reduction in menstrual 
bleedings occurs and amenorrhea is encountered in 20–30% of LNG-IUS users (Xiao et al., 1995). The 
LNG-IUS offers a safe, convenient, and  inexpensive route for progestin-therapy, and it seems to offer 
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good symptom control in cases of peritoneal endometriosis (Vercellini et al., 2003, Lockhat et al., 
2004, 2005), and RVE (Fedele et al., 2001). Moreover, the effect of the LNG-IUS on recurrent 
endometriosis-associated pain has been shown to be equally good as that associated with GnRH 
analogues (Petta et al., 2005). LNG-IUS use does not suppress ovulation and therefore levels of 
circulating estradiol remain within the range observed in women of reproductive age (Nilsson et al., 
1980). The positive effects on pain therefore most likely result from local effects on ectopic 
endometrium, and possibly from reduction of retrograde menstruation. 
Progestogens have also been compared with repeat surgery in the treatment of recurrent 
dyspareunia associated with DIE (Vercellini et al., 2012). Both treatment modalities were equally 
good and improved the quality of life, but the effects of progestogen became apparent more 
gradually over time, whereas surgery offered pain relief immediately and the effects diminished with 
time (Vercellini et al., 2012). New evidence shows that hormonal therapies reduce the size of 
rectovaginal nodules (Ferrero et al., 2013), which partly explains their efficacy in relieving pain. 
 
Table 3. Studies (with > 20 patients) on progestogens and COCs in the treatment of RVE with or 










LNG-IUS=levonorgestrel-releasing intrauterine system 
 
 
*Only patients with rectovaginal endometriosis considered 
** All patients had colorectal endometriosis 
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Authors Study design No of patients Intervention Duration of 
treatment 
Main result 




90 2 10 g C A 
3 mg/day vs. 
NETA 2.5 
mg/day 









59* Vaginal EE2 
15 g ETO  120 
g/day vs. 
transdermal 
EE2 20 g  N  
150 g/day 






























40** NETA 2.5 
mg/day 










26** EE2 150 g ES 
60 g/day 













25 DN  2 mg/day 6 months pain 
significantly 
reduced 





144 DE  75 g/day 
vs. COC 













143** DE  75 g/day 
vs. vaginal EE2 
15 g ETO  
120 g/day 










7.4 Aromatase inhibitors 
 
As estradiol is excessively synthesized in endometriotic tissue through the action of aromatase, it is 
logical that aromatase inhibitors offer a good treatment option. Aromatase inhibitors suppress 
estrogen synthesis locally in endometrial and endometriotic tissue. Decreased estrogen levels 
stimulate the pituitary secretion of FSH and act as ovulation inducers. Hence, in fertile-aged women 
aromatase inhibitors need to be combined with progestins, COCs, or GnRH analogues (Ferrero et al., 
2011). In RVE, letrozole, 2.5 mg daily combined with norethisterone acetate (2.5 mg/day) has proved 
beneficial (Remorgida et al., 2007, Ferrero et al., 2009). However, such combination therapies among 
fertile-aged women are not the first-line therapies, as beneficial effects can also be achieved by using 






8. Other medical options in endometriosis 
 
During the past few decades, several promising pharmacological agents – such as 
immunomodulators, selective progesterone receptor modulators (SPRMs), GnRH antagonists, 
antiangiogenic agents, and melatonin – have been tested regarding their efficiency in relieving 
endometriosis-associated pain. 
The use of GnRH antagonists in the treatment of endometriosis pain has recently been introduced. 
GnRH antagonists have a molecular structure that enables their use orally (Ezzati and Carr, 2015). 
They reduce estrogen levels without triggering severe side effects, as the initial peak in gonadotropin 
secretion is lacking (Kupker et al., 2002). 
SPRMs such as mifepristone, ulipristal acetate and asoprisnil represent a group of progesterone 
receptor ligands that display progesterone agonist, antagonist, or mixed agonist–antagonist effects 
depending on the target tissue. Their daily use induces amenorrhea by mechanisms that are partly 
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unknown. It seems that they inhibit ovulation without reducing the levels of circulating estradiol 
(Chabbert-Buffet et al., 2012). Early studies have shown promising results as regards their efficacy 
and tolerability in managing endometriosis-associated pain (Chwalisz et al., 2005). 
The antiangiogenic agent bevacizumab (Avastin) has proved beneficial in reducing the growth of 
endometriotic implants in mice, and, therefore, may offer a novel therapeutic option sometime in 
the future (Ricci et al., 2011).  Overall, a huge amount of pharmacological agents have been tested for 
the treatment of endometriosis, but none of these in cases of RVE (Vercellini et al., 2008, Zito et al., 
2014, Ferrero et al., 2015). Moreover, medical therapy as a treatment option for RVE has aroused 






9. Surgical treatment of RVE 
 
9.1  Radical resection is the main goal 
 
In patients who do not respond to hormonal therapies, or among patients with side effects from 
hormone use or those who wish for pregnancy, the gold standard for the treatment of symptomatic 
RVE is surgery (Abbott et al., 2004, Chapron et al., 2004, Dunselman et al., 2014). RVE is not 
considered a progressive disease and therefore asymptomatic patients do not need to undergo 
operation (Koninckx et al., 2012). Surgery is in theory based on straightforward oncologic principles, 
i.e. radical excision of all visible and palpable lesions (Abbott et al., 2004, Chapron et al., 2004, 
deCicco et al., 2011, Koninckx et al., 2012). The posterior vaginal wall may need to be resected if 
endometriosis infiltrates the posterior fornix. The surgical procedure is described in detail in 
Publication I. As most patients affected by endometriosis are of fertile age, it adds to the challenges 
of RVE surgery – the surgery needs to be radical but at the same time as conservative as possible, as 




9.2 Diagnosis and preoperative assessment of RVE 
 
Rectovaginal endometriosis should always be suspected among women of fertile age with 
invalidating dysmenorrhea, deep dyspareunia or typical bowel symptoms. By way of clinical 
examination, approximately 50% of DIE lesions over 3 cm in diameter can be diagnosed (Koninckx et 
al., 1996). Laparoscopy is the gold standard for the diagnosis of endometriosis. However, as RVE 
noduli are located retroperitoneally, and often associated with cul-de-sac obliteration, magnetic 
resonance imaging (MRI) should be used preoperatively as a diagnostic tool to identify all RVE 
noduli and possible colorectal involvement. Colorectal involvement can also be diagnosed with the 
use of ultrasonography (US). The sensitivity and specificity of US in diagnosing colorectal 
involvement have been reported to be as high as 85–100% (Hudelist et al., 2011), but in real life it 
seems that the accuracy of US varies according to the expertise of the user. MRI has proved to be 
accurate in the diagnosis of RVE and bowel involvement (and the degree of bowel stenosis) (Bazot et 




9.3 rAFS classification of endometriosis is used in surgery 
 
During surgery, the severity and extent of endometriosis should be classified. The most commonly 
used classification system was proposed in 1979 by the American Fertility Society. A few years later, 
the classification system was revised (rAFS 1985). This revised American Fertility Society (rAFS) 
classification divides endometriosis into four categories (I–IV) depending on the severity of the 
disease (where rAFS I is mild endometriosis and rAFS IV is severe endometriosis). This classification 
system was originally meant to predict future fertility – the highest scores result from adnexal 
involvement of endometriosis whereas deep lesions do not necessarily result in advanced staging III-
IV (unless the cul-de-sac is obliterated). Therefore, several attempts have been made to develop a 
better classification system that would systematically take into account the DIE lesions (Adamson 
2011).  
The ENZIAN classification system was developed for better description of DIE and its involvement in 
the pelvic structures and organs, and it supplements the rAFS score (Haas et al., 2011). However, use 
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of the ENZIAN classification is somewhat complex, and therefore it has not achieved great 
popularity, and for the majority of cases rAFS scoring is still used. 
 
9.4 RVE with colorectal involvement – surgical options 
 
RVE extending to the bowel wall is estimated to be present in 4–12% of RVE cases (Jerby et al., 1999, 
Remorgida et al., 2007, Wills et al., 2008). The rectosigmoid colon is the most common site of 
gastrointestinal involvement (Zanetti-Dällenbach et al., 2008). Even though surgical management is 
considered the primary treatment for symptomatic RVE with colorectal extension (Garry 2004, 
Emmanuel and Davis, 2005), the most appropriate approach still remains controversial. Laparoscopy 
has evolved tremendously over the past decades and a laparoscopic approach to colorectal surgery in 
RVE has become the method of choice during the past few years (Jerby et al., 1999, Darai et al., 2010, 
Meuleman et al., 2011, Ruffo et al., 2012, Ruffo and Rossini 2013, Wolthuis et al., 2014).  
Different surgical options include shaving (excision without opening the bowel wall), full-thickness 
disc excision (defined as excision with opening of the bowel wall followed by its closure) or bowel 
resection (and anastomosis) (Figure 5). The choice of the operative technique depends not only on 
the extent and depth of bowel endometriosis, but also on the surgical choice of the center. Some 
groups seem to favor bowel resection as the treatment of choice (Duepree et al., 2002, Darai et al., 
2005, Dubernard et al., 2006) whereas others avoid bowel resection whenever possible (Donnez et 
al., 1997, Vercellini et al, 2006, Koninckx et al, 2012). It seems that in cases with large (over 3 cm) or 
multiple nodules, discoid resection often results in incomplete excision of endometriotic lesions, and 
therefore, symptom relief may not be achieved (Remorgida et al., 2005). In addition, excision of such 
large noduli may result in stenosis of the bowel lumen (Abrao et al., 2015). On the other hand, in less 
extensive cases, discoid resection has been reported to be a safe alternative to bowel resection, with 
less postoperative morbidity (Fanfani et al., 2010). More conservative surgical techniques (shaving, 
excision) have been suggested to lead to better functional outcomes in women with rectal 
endometriosis (Roman et al., 2013). Currently, however, 70% of patients who need colorectal surgery 
for RVE undergo bowel resection, and in the majority of cases, via laparoscopy (for review see 











10. Complications of RVE surgery 
 
The rates of major intra- and postoperative complications following laparoscopic surgery for DIE in 
large specialized centers vary from 2.1 to 13% (Vercellini et al., 2009, Kondo et al., 2010, Milone et al., 
2015). Colorectal surgery increases the risk of complications; the overall complication rate following 
bowel resection in cases of RVE (either in laparoscopy or in laparotomy) is 22% – major 
complications occur in 11% of women (for review see DeCicco et al., 2010). Therefore, colorectal 
resections should always be performed by colorectal surgeons. Risk factors for the development of 
major complications in bowel resections are opening of the vagina at the time of surgery, and the 
treatment of low rectal lesions (< 5–8 cm from the anal verge) (Ruffo et al., 2010, Meuleman et al., 
2011). In these cases, protective loop ileostomy may be needed (Wolthuis et al., 2014).  
The majority of severe complications in colorectal surgery are bowel complications such as 
inadvertent rectal perforation or anastomotic leakage (Oliveira et al., 2015). The second most 
frequent major complication is rectovaginal fistula formation, with a 0–10% risk (Duepree et al., 
2002, Darai et al., 2005). Other major complications include intra-abdominal bleeding, urinary tract 
injuries or fistulas, and pelvic abscesses and collections. Colostomy is often needed to treat severe 
35 
 
bowel complications, and the decision to possibly perform a bowel resection should be discussed 
and agreed upon with a patient prior to the operation.  
The most common minor postoperative difficulty is urinary retention, probably due to damage to 
the parasympathetic plexus, resulting in temporary bladder denervation. This problem often occurs 
in connection with colorectal surgery (Dubernard et al., 2008). Nerve-sparing techniques have been 
suggested in order to avoid bladder dysfunction (Volpi et al., 2004, Possover et al., 2005, Landi et al., 
2006). In these techniques, the key point is to dissect the posterior parametrium accurately so that 
damage to the hypogastric inferior nerve plexus is avoided. This can be done by starting the 
dissection from the side with more extensive disease, therefore leaving the nerves on the “better” 
side untouched. 
 
11. Effect of surgery on pain and quality of life 
 
Since 2000, there have been numerous studies carried out to evaluate the effect of RVE surgery on 
pelvic pain symptoms (for review see Vercellini et al.,2009). However, the definition and extent of 
RVE reported in the literature have been highly variable (RVE or RVE with colorectal involvement) 
and the same applies to the surgical procedure (laparotomy, laparoscopy, bowel surgery performed 
or not). Vercellini et al. (2006) compared surgery with expectant management in RVE patients 
suffering from pain symptoms and infertility. A statistically significant delay in symptom recurrence 
was observed in favor of the surgery group. The benefit of surgery was particularly evident as regards 
deep dyspareunia and dyschezia. 
Overall, surgery for RVE seems to result in long-term pain relief (Fedele et al., 2004) and improved 
quality of life (Garry et al., 2000, Abbott et al., 2004, Ford et al., 2004, Setälä et al., 2012). Among 
women with RVE extending into the colorectum, pain relief following laparoscopic colorectal surgery 
is achieved in up to 85% of women in 12 months’ follow-up time (Bassi et al., 2011). Laparoscopic 
colorectal resections also result in significantly improved quality of life (Table 4).  
Recurrence rates following RVE surgery, defined as recurrence of lesions, or recurrence of pain, vary 
between 5–30% (DeCicco et al., 2011, Meuleman et al., 2011, Koninckx et al., 2012). Bowel resection 
seems to reduce the risk of symptom recurrence (Fedele et al., 2004), probably due to the 
completeness of resection. In women with recurrent disease, pain alleviation is usually achieved with 
hormonal therapy (Vercellini et al.,2003). If repeat surgery is considered, hysterectomy with bilateral 
oophorectomy produces the best results (Vercellini et al., 2009). 
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Table 4. Studies carried out to assess the quality of life following laparoscopic colorectal resection. 









et al., 2006 
Prospective 58 SF-36 22.5 QoL  
Tenesmus,  
constipation not improved 
Bassi et al., 
2011 
Prospective 151 SF-36 12 QoL  
Meuleman et 
al., 2011 




27 QoL  
Kössi et al., 
2013 
Prospective 26 15-D 12 QoL  , sexual well-being 
improved 
Ribeiro et al., 
2014 
Prospective 40 SF-36 12 QoL  
Silveira da 
Cunha 
Araujo et al., 
2014 





26 * SF-36 51 QoL  in both groups 
Kent et al., 
2015 
Prospective 137 EQ-5D 12 QoL , pelvic clearance** 
improved outcome 
 
SF-36=Short form-36 Health status and the quality of life survey 
EQ-5D=Euro Quality of Life Five Dimensions Questionnaire 
* Bowel resections (n=52) undertaken via laparoscopy (n=26) or laparotomy (n=26) were compared 











12. Role of postoperative hormone treatment in RVE 
 
Regarding RVE, no studies have been conducted on the postoperative use of HT in the prevention of 
symptom recurrence. According to the results of a pilot study by Vercellini et al. (2003), 
postoperative insertion of an LNG-IUS significantly decreased the risk of symptom recurrence 
compared with endometriosis surgery only. However, the patients were not suffering from DIE. 
Recently, Bayoglu Tekin et al. (2011) compared the efficacy of a postoperatively inserted LNG-IUS to 
GnRH analogue treatment (for six months) in cases of severe endometriosis (rAFS stage IV). Both 
modalities showed comparable effectiveness in reducing pain during the 12-month follow-up time 
(Bayoglu Tekin et al., 2011). Moreover, postoperative COC use has been shown to decrease the risk of 
ovarian endometrioma recurrence (Vercellini et al., 2013). For these reasons, it has been suggested 
that the LNG-IUS and combined oral contraceptives may be helpful in preventing the recurrence of 
dysmenorrhea after surgery (Abou-Setta et al., 2006, Somigliana et al., 2014). New ESHRE guidelines 



















AIMS OF THE STUDY 
 
This study was undertaken to investigate the long-term effects of surgery in the treatment of RVE. In 
addition, the significance of nerve fibers in RVE-associated pain was investigated. 
 
Specific aims of the study were: 
1. To study the long-term outcome of surgery in terms of pain recurrence 
2. To identify factors associated with recurrence  
3. To identify factors predisposing to bowel resection 
4. To study the feasibility of laparoscopic access as regards bowel resection 





















MATERIALS AND METHODS 
 
Approval to perform this study was granted by the Hospital District of Helsinki and Uusimaa 
(6.4.2004 Dnro 125/E9/06).  
 
1. Surgical data on RVE (Studies I, III) 
 
Study I covered all operations performed for RVE – with or without bowel resection – between 
January 2000 and May 2004 at the Department of Obstetrics and Gynecology, Helsinki University 
Central Hospital (n = 153). Study III was focused on bowel resections; therefore, only operations in 
which bowel resection was performed were included in the time period from June 2004 until the end 
of 2012 (n = 164). 
The patient data were obtained from hospital charts. The demographic data included age and BMI at 
the time of surgery as well as history of pregnancies, contraception, other hormonal therapies, 
symptoms, and prior operations. 
Surgical data included the method of access (laparoscopy or laparotomy), operative details, rAFS 
(revised American Fertility Society) classification (1985), and peri-operative and postoperative 
complications. Regarding operations with bowel resection (Study III), data on the length of resected 
bowel, the size and number of noduli in resected bowel, the level of anastomosis and the need for 
ileostomy or colostomy were obtained.  Data concerning fertility and reoperations following surgery 
were also collected. In addition, the rate of complications (“learning curve”) associated with the main 










2. Patients in Study II 
 
In order to evaluate the long-term effects of surgery, and especially the factors associated with 
recurrence, patients operated upon between January 2002 and May 2004 were offered a follow-up 



























12 excluded (2 due to 




23 refused due to 




33 refused (no specific 
reason) or could not be 
reached




Prior to assessment at the clinic, patients were asked to fill in a symptom diary for 30 consecutive 
days. The severity of dysmenorrhea, deep dyspareunia, non-menstrual pelvic pain, and dyschezia 
were separately evaluated each day using a visual analogue scale (VAS). The amount of uterine 
bleeding was also assessed each day using a 4-point scale (0 = no bleeding, 1 = spotting , 2 = light 
bleeding, 3 = regular bleeding, and 4 = heavy bleeding).  
 
At the follow-up visit, recurrence of the disease was diagnosed clinically on the basis of pelvic 
examination. Data on hormonal therapies used, pregnancies and reoperations were collected. 
Current symptoms were evaluated on the basis of symptom diaries. A sum score for each symptom 
and each patient was calculated from 30 daily VAS assessments (0–10) by adding the daily VAS 
scores. Thus, the maximum sum score for each symptom was 300. In addition, an overall symptom 
sum score was obtained as a mean of the four separate symptom scores. Similarly, a bleeding sum 






















3. Tissue samples and immunohistochemistry (Study IV) 
 
In order to study the types and densities of nerve fibers in RVE, permission to reexamine samples 
removed during the index surgery was obtained at the time of the follow-up visit. Altogether, 45 RVE 
specimens were eligible for reexamination, and subjected to immunohistochemical staining, as 
shown in Table 5. The types and densities of nerve fibers were thereafter analyzed as regards the 
association of nerve fibers with various patient characteristics such as hormone use. 
 
 
Table 5.  List of antibodies and optimal dilutions used in immunohistochemical staining. 
Antibody* Antigen target retrieval
Dilution of primary 
antibody
Marker of
PGP9.5 pH 9 1:1,400 all nerve fibers
NPY pH 6 1:8,000
sympathetic 
fibers
VIP No Target Retrieval 1:5,000
parasympathetic 
fibers
SP pH 9 1:8,000 sensory fibers
NGF pH 9 1:500
TrkA pH 9 1:500
main receptor 
of NGF










4. Statistical analysis 
 
Univariate and multivariate association models were used to identify the risk factors for bowel 
resection (Study I). 
The factors associated with clinical recurrence (Study II) were evaluated by using univariate and 
multivariate logistic regression models. Odds ratios (ORs) with 95% confidence intervals (CIs) and p-
values were reported. The statistical analyses were performed by StatFinn Oy (Espoo, Finland).  The 
statistical software used was SAS V 9.1 for Windows. 
 
In Study III, statistical analysis was performed using PASW 18.0 for Mac (SPSS Inc., Chicago, IL, 
USA). In Study IV, the data were analyzed using IBM SPSS 19.0 Statistics (Armonk, New York, USA). 
Differences in continuous variables were analyzed by means of the Mann–Whitney U-test for skewed 
data. The chi-squared test was used for independent nominal data, presented as n (%). Three levels 
of anastomosis (low, medium or high) as well as three 3-year periods (2004–2006, 2007–2009 or 
2010–2012) were compared by using the chi-squared linear-by-linear association test. The level of 





















1. General aspects 
 
Between January 2000 and May 2004, a total of 153 operations were performed for RVE; 57 patients 
(37%) were treated laparoscopically, and 96 patients (63%) via laparotomy. Fifty-four patients (35%) 
underwent bowel resection. There were four major complications (2.6%) requiring further surgery. 











2. Risk factors of bowel resection 
 
The risk of bowel resection was increased among patients with previous surgery for endometriosis, 
intestinal symptoms, or rAFS score IV. Preoperative use of combined oral contraceptive pills was 




Univariate associations between various demographic, preoperative and perioperative factors, and bowel 




p-value 95% CI 95% CI 
Age 1.02 0.96 1.08 0.47 
History of infertility 1.30 0.63 2.66 0.48 
revious surgery 2.74 1.35 5.54 0.005 
reoperative use of COCs (vs. no 
contraception) 
0.32 0.15 0.66 
Preoperative symptom          
Dysmenorrhea 0.84 0.43 1.65 0.61 
elvic pain 0.91 0.46 1.82 0.79 
Dyspareunia 0.57 0.28 1.16 0.12 
Dyschezia or rectal bleeding 2.55 1.29 5.02 
rAFS III (vs. I II) 2.04 0.77 5.41 0.15 









3. Recurrence following RVE surgery 
 
Altogether, 60 patients participated in the follow-up study. The mean time (  SD) from index 
surgery to clinical evaluation was 4.0  0.5 years. Patients presented with low symptom sum scores 
on the basis of symptom diaries (n=51). The median symptom sum scores (max 300) for each 





Table 8. Median symptom sum scores (range) in 51 symptom diaries for each endometriosis-associated 
symptom. The sum score for each symptom was calculated by adding 30 daily VAS scores (0–10) (theoretical 
maximum of 300). 
 
Symptom Median symptom sum score (range) 
Dysmenorrhea 3 (0-32) 
Pelvic pain 9 (0-72) 
Dyspareunia 0 (0-52) 
Dyschezia 2 (0-76) 
 
 
Evidence of RVE recurrence on pelvic examination was found or suspected in 29 (48%) of the 
subjects.  Detection of clinical recurrence was not associated with pain symptoms. In univariate 
analysis, amenorrhea (bleeding sum score = 0 in the symptom diary) at the time of clinical 
assessment was associated with a lower risk of recurrence. Undergoing bowel resection was of 
borderline significance in protecting women from recurrence. In multivariate analysis, the protective 









Table 9. Factors associated with clinical RVE recurrence.  
Each symptom was considered prevalent if the symptom sum score exceeded 3. The symptom sum score was 
calculated by adding 30 daily VAS scores (0–10) (theoretical maximum of 300). 
 
HT = hormonal therapies 
 
 
Factor Univariate analysis Multivariate analysis 
 OR (95% CI), p-value OR (95% CI), p-value 
Age 0.92 (0.82–1.03), 0.14  
Smoking 1.05 (0.33–3.30), 0.94  
Previous endometriosis surgery 0.59 (0.21–1.66), 0.32  
Bowel resection at index surgery 0.37 (0.13–1.07), 0.07 0.23 (0.06–0.89), 0.03 
HT postoperatively 2.31 (0.81–6.54), 0.12  
Prevalent dysmenorrhea 1.31 (0.38–4.50), 0.67  
Prevalent pelvic pain 0.71 (0.23–2.22), 0.56  
Prevalent dyschezia 0.59 (0.16–2.09), 0.41  




4. Outcome of colorectal surgery 
 
Between June 2004 and December 2012 a total of 164 rectosigmoid resections for RVE were 
performed, of which 112 (68%) were undertaken laparoscopically and 52 (32%) by way of laparotomy. 
The proportion of laparoscopic bowel resections increased towards the end of the study period. The 
rate of major complications was 12% both in laparoscopies and in laparotomies. The rate of 
complications in laparoscopies decreased from 27% in 2004–2006 to 8% between 2010 and 2012 
(Table 10). Similarly, the complication rate associated with the main gynecological surgeon in 




A greater size (  4 cm) of a nodule in resected bowel was significantly associated with the 
development of a major complication (Table 10). During the median follow-up period of 61 months 
(range 16–116 months) 7% of cases needed reoperation due to recurrence. Forty-seven percent of 
those women who preoperatively desired a pregnancy subsequently had a child. 
 
Table 10. Factors associated with major complications in 164 colorectal resections. (The level of 
anastomosis was that measured from the anus.) 
Variable n (%) Number of complications 
(%) 
p-value 
Nodule size  4 cm  87 (53%) 6 (7%) 0.04 
Nodule size  4 cm  68 (41%) 12 (18%)  
    
 15 (9%) 3 (20%) 0.26* 
Medium anastomosis (6–9 cm) 102 (62%) 12 (12%)  
 47 (29%) 4 (9%)  
    
Operation during 2004–2006 49 (30%) 10 (20%) 0.04* 
Operation during 2007–2009 48 4 (8%)  
Operation during 2010–2012 67 5 (7%)  
    
Laparoscopy 112 13 (12%)  
Laparotomy 52 6 (12%)  
 





5. Nerve fibers and the effects of HT  
 
Altogether, 45 RVE specimens removed in surgery were immunohistochemically analyzed regarding 
the presence and density of nerve fibers. The use of hormonal therapy was associated with reduced 
densities of sympathetic, parasympathetic and sensory nerve fibers in DIE lesions. The density of 
total nerve fibers (assessed by using pan-neuronal marker PGP9.5; see Figure 7) was significantly 
lower (p < 0.05) in lesions collected from women receiving HT (8.6/mm², 4.2–20.8/mm²; median 
density, from 25th to 75th quartile) compared with that in lesions from untreated women (24.9/ mm², 
11.2–34.9/mm²). This is illustrated in Figure 2 in Publication IV. RVE lesions stained strongly for NGF 
and its receptor Trk-A. Expression of NGF, but not that of Trk-A, was significantly reduced during 
use of hormonal therapy. 
 
Figure 7. Immunohistochemical staining of endometriotic tissue with the pan-neuronal marker PGP9.5 












Deep infiltrating RVE is one of the most challenging conditions in the field of gynecology. It causes a 
large amount of suffering and pain, and affects women in their best reproductive years. The 
mechanisms of pain generation are poorly understood. Surgery is demanding, with a risk of severe 
complications. The significance of bowel resection is controversial. We conducted this study to 
clarify these compelling aspects with an emphasis on evaluating the long-term effects of surgery in 
patients with RVE. Moreover, the effects and mechanisms of HT in RVE were to be studied, as only a 
few studies exist on the use of HT in RVE-associated pain.   
The ultimate origin of endometriosis-associated pain may remain a mystery, but nevertheless, 
several mechanisms for the development of pain have recently been recognized. It seems that 
endometriosis is a complex neuroinflammatory disease, and inflammatory mediators such as NGF 
seem to have a central role in generating pain (Stratton and Berkley 2011). NGF mediates 
inflammation, and induces the growth of vessels and nerve fibers in the endometriotic tissue 
(McKinnon et al., 2015). Moreover, NGF seems to have a key role in sensitizing nerve endings (Anaf 
et al., 2000). 
Even though most hormonal therapies reduce inflammation, our study shows that the expression of 
NGF and its receptor Trk-A are only partially suppressed during the use of HT – a fact that could 
possibly explain the limited efficacy of HT in some endometriosis patients. Interestingly, as estrogen 
is known to stimulate NGF secretion, the autonomous estrogen synthesis in endometriotic tissue 
may be the fundamental mechanism in maintaining inflammation and persistent pain in patients not 
responding to HT.  
New evidence shows that HT may, however, work better than has been previously thought in RVE-
associated pain (Vercellini et al., 2009, Maggiore et al., 2014). Most forms of HT (COCs and 
progestogens) suppress ovulation and therefore reduce the levels of circulating endogenous 
estradiol. Endometriosis being estrogen-dependent, this mechanism of action seems fundamentally 
important. In addition, systemic progestogens also seem to have local effects as they reduce the size 
of RVE nodules (Vercellini et al., 2003, Ferrero et al., 2013). This local effect may be the result of 
decidualization and the subsequent atrophy of endometriotic tissue (Jones et al., 2000). 
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Interestingly, the LNG-IUS has also proved to work well in recurrent endometriosis pain (Petta et 
al.,2005). Therefore, ovulation inhibition may not be the central mechanism of action of all 
hormonal therapies – the majority of LNG-IUS users experience ovulations by the end of the first 
year of use (Nilsson et al., 1984). Reduction of retrograde menstruation – and the subsequent 
reduction of shed endometrium in the abdominal cavity – may play a crucial role in achieving pain-
relief (Petta et al., 2005). Eutopic endometrium in endometriosis patients has several 
proinflammatory properties that are absent in healthy endometrium (Bulun, 2009).   
Inflammatory processes also contribute to nerve sprouting, present to a great degree in 
endometriosis (Stratton and Berkley, 2011). Increased densities of sympathetic, parasympathetic and 
sensory nerve fibers have been identified in endometriotic lesions, and the innervation seems to be 
exceptionally dense in cases of RVE (Morotti et al., 2014). Our studies further confirm these findings. 
Interestingly, nerve fiber densities in RVE samples (removed at surgery) from hormone-users 
(progestogens, COCs) were lower than those in samples from non-users. This same finding of HT 
reducing the density of nerve fibers has been shown in previous studies (Tokushige et al., 2008, 
2009). Quite possibly, this may be one of several mechanisms of action of HT in reducing pain 
symptoms in endometriosis. The partial suppression of NGF may be one of the explanations for the 
reduction in the densities of nerve fibers. 
Surgery is needed when conservative treatment with HT does not lead to pain alleviation. Our 
results show that surgery for RVE is beneficial as regards long-term pain relief. The majority of 
patients who have undergone an operation for RVE remain symptom-free in the following years. 
Their reproductive performance also seems reasonably good, as almost half of those who wish for 
pregnancy succeed in their attempts. Interestingly, the majority of patients with persisting 
endometriosis symptoms after the operation have no clinical findings of RVE. This same finding has 
been documented in an earlier study (Abbott et al., 2003). This may imply that persistent pain in 
some cases is neuropathic in nature.  
According to our results, in one third of RVE operations colorectal surgery is performed. This is in 
line with the results of previous studies (Jerby et al., 1999, Remorgida et al., 2007). During the past 
ten years the approach as regards colorectal surgery in RVE patients has changed. Most operations 
for RVE – with or without bowel involvement – are currently approached via laparoscopy. This shift 
towards a laparoscopic approach was also seen in our institute during our study period of 2000 to 
2012. Laparoscopy offers fast and less painful recovery for patients, and it offers an optimal and 
precise view of the pelvic anatomy for the operating surgeon. However, laparoscopy for RVE 
demands expertise and repetition. In our study, we showed that the rate of complications is 
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associated with the experience of the operating surgeon. In addition, it seems that the rate of 
complications is higher in bowel resections performed because of RVE compared with bowel 
resections performed for other reasons (Dalton et al., 2009). Therefore, as RVE is not very common, 
centralizing these operations is essential in order to achieve the best possible results. Moreover, all 
laparoscopic bowel resections should be performed by colorectal surgeons in order to minimize the 
rate of complications. This has always been the practice in our institution. 
Complication rates in the operations involving bowel resection in our study were not as high as 
those reported previously; rates as high as 22% have been reported (deCicco et al., 2011). We found 
that major complications develop in 12% of these operations performed either via laparoscopy or 
laparotomy – the risk of complications increases with more extensive disease (large or multiple 
nodules). However, these complications are potentially life-threatening, and in most cases demand 
colostomy for treatment in otherwise healthy young patients suffering – after all – from a benign 
condition. Therefore, it is understandable that some groups advocate a more conservative approach 
to bowel resection and favor performing shaving or, in cases of lesions penetrating the bowel wall 
through the muscularis layer, full-thickness discoid excision instead of bowel resection (Koninckx et 
al. 2012). It has been suggested that a more conservative approach to bowel surgery might result in 
better functional outcomes, and therefore, shaving and discoid excision should probably be 
considered in RVE with a nodule not larger than three centimeters (Remorgida et al., 2005, Roman et 
al., 2013).  
Even though the most appropriate approach to bowel surgery may remain controversial, the fact is 
that in two thirds of patients who need colorectal surgery the choice currently is rectosigmoid 
resection (Meuleman et al., 2011). Our study proved that bowel resection is very likely to take place if 
the preoperative symptoms include rectal bleeding or pain during defecation. In addition, patients 
with a history of previous operations for RVE are at increased risk of needing colorectal surgery. This 
undoubtedly implies that prior surgery has not been radical enough for adequate symptom relief.   
As recurrence – meaning recurrent pain or lesions – following surgery represents one of the major 
concerns in the surgical treatment of RVE, it is important to take all possible measures in order to 
reduce their number. Recurrence of DIE can be considered to be a result of incomplete surgery 
(Koninckx et al., 2012). Even though performing bowel resection carries risks in terms of 
complications, we found that it seems to have a protective effect against recurrences, most likely 
because of the completeness of resection. This finding is in accordance with that in an earlier study 
(Fedele et al, 2004). During the past ten years, endometriosis surgery has evolved greatly. Instead of 
patients undergoing several minor operations, the current aim is to carry out one major operation by 
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a multidisciplinary team – and to be as radical as possible without compromising future fertility. This 
approach has already been shown to reduce the rates of recurrence (Carmona et al., 2009). 
All treatments – either surgical or hormonal – resulting in the absence of menstrual bleeding seem to 
protect women from recurrences. Therefore, hysterectomy should be considered for women who no 
longer plan to have new pregnancies. Most importantly, HT with the aim of amenorrhea should be 
tailored for all women following surgery. Continuous use of COCs, or the use of progestogens are 
simple choices of therapies that result in amenorrhea. The LNG-IUS also appears to be effective in 
reducing the amount of bleeding (Hurskainen et al., 2004). 
In conclusion, endometriosis is a complex inflammatory disease with abundant nerve fibers present 
in endometriotic tissue. Inflammation contributes independently to pain generation, and also 
stimulates the growth of nerve fibers in endometriotic lesions. Local estrogen production has a 
proinflammatory role, as estrogen stimulates the synthesis of prostaglandins (Bulun, 2009). Pain 
symptoms may respond to hormonal therapies, but in women who do not benefit from their use, 
surgery is needed. Bowel resection may protect women from recurrences in cases of colorectal 
involvement. In all women, following operative treatment for RVE, hormonal therapies aimed at 
amenorrhea should be administered in order to protect them from symptom recurrence. Recurrent 
symptomatic disease, however, is very uncommon, and most patients greatly benefit from surgical 

















The following conclusions can be drawn on the basis of the current work: 
1. Surgery for RVE results in long-term symptom relief and therefore seems beneficial for those 
patients in which symptom control cannot be achieved by the use of hormonal treatments. 
 
2. Performing bowel resection, when endometriosis extends to the bowel wall, most likely 
protects women from symptom recurrence. In addition, all treatments – both hormonal and 
surgical – that result in the absence of menstrual bleeding significantly reduce the risk of 
recurrence. 
 
3. Patients with previous endometriosis surgery and intestinal symptoms such as rectal 
bleeding or pain during defecation are at increased risk of undergoing bowel resection.  
These patients should be informed of this procedure prior to surgery. 
 
4. Laparoscopy offers a safe approach for RVE surgery, even in cases where colorectal surgery is 
needed. The rate of complications in laparoscopies does not differ from that seen in 
laparotomies. 
 
5. Rectovaginal lesions are richly innervated by sympathetic, parasympathetic and sensory 
nerve fibers. Hormonal therapies reduce the density of these nerve fibers, and this may 
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